Ignite Creation Date:
2024-05-06 @ 7:11 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05921318
Status:
RECRUITING
Last Update Posted:
2023-06-27
First Post:
2023-06-19
Brief Title:
Beijing Protocol in Patients Receiving More Than 510 HLA-mismatched Allo-HSCT
Sponsor:
Peking University Peoples Hospital
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
The Safety and Efficiency of Beijing Protocol in Malignant Hematologic Disease Patients Receiving More Than 510 HLA-mismatched Allo-HSCT
Status:
RECRUITING
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 510 HLA-mismatched allo-HSCT
Detailed Description:
Allogeneic hematopoietic stem cell transplantation allo-HSCT is a potentially curative procedure for patients with hematological malignanciesDonor-recipient human leukocyte antigen HLA compatibility plays a key role in successful allo-HSCT as HLA-matching has a direct impact on the risk of GvHD non-relapse mortality NRM and survival Suitable matched or haploidentical donors are not always available or accessible even in the era of the international registriesTherefore there is a need for new strategies that could negate the barrier of HLA-mismatching allowing allo-HSCT from traditionally prohibitive highly mismatched donorsThe aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 510 HLA-mismatched allo-HSCT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None